Journal
ENDOCRINOLOGY AND METABOLISM
Volume 38, Issue 1, Pages 25-33Publisher
KOREAN ENDOCRINE SOC
DOI: 10.3803/EnM.2022.1642
Keywords
Glucagon-like peptide 1; Diabetes mellitus; type 2; Renal insufficiency; chronic
Categories
Ask authors/readers for more resources
The therapeutic benefits of GLP1 for people with type 2 diabetes and/or obesity are well-established. They should replace traditional treatment options and have potential for treating other conditions such as fatty liver disease and Alzheimer's disease.
The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations by professional guidelines suggest that GLP1 receptor agonists should replace more traditional treatment options such as sulfonylureas and dipeptidyl-peptidase 4 (DPP4) inhibitors. Furthermore, their benefits in reducing cardiovascular events in people with type 2 diabetes beyond improvements in glycaemic control has led to numerous clinical trials seeking to translate this benefit beyond type 2 diabetes. Following early trial results their therapeutic benefit is currently being tested in other conditions including fatty liver disease, kidney disease, and Alzheimer's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available